Search

Your search keyword '"Petrowsky H"' showing total 359 results
Start Over Author "Petrowsky H"
359 results on '"Petrowsky H"'

2. Liver transplantation in recipients receiving renal replacement therapy: outcomes analysis and the role of intraoperative hemodialysis.

Author

Agopian, VG, Dhillon, A, Baber, J, Kaldas, FM, Zarrinpar, A, Farmer, DG, Petrowsky, H, Xia, V, Honda, H, Gornbein, J, Hiatt, JR, and Busuttil, RW

Subjects
Humans, Kidney Diseases, Postoperative Complications, Prognosis, Intraoperative Care, Renal Dialysis, Liver Transplantation, Survival Rate, Retrospective Studies, Follow-Up Studies, Prospective Studies, Recovery of Function, Graft Survival, Adult, Middle Aged, Female, Male, End Stage Liver Disease, Hemodialysis, liver transplantation, outcomes, pretransplant renal failure, renal disease in liver transplantation, Surgery, Medical and Health Sciences
Abstract

The Model for End-Stage Liver Disease (MELD) system has dramatically increased the number of recipients requiring pretransplant renal replacement therapy (RRT) prior to liver transplantation (LT). Factors affecting post-LT outcomes and the need for intraoperative RRT (IORRT) were analyzed in 500 consecutive recipients receiving pretransplant RRT, including comparisons among recipients not receiving IORRT (No-IORRT, n = 401), receiving planned IORRT (Pl-IORRT, n = 70), and receiving emergent, unplanned RRT after LT initiation (Em-IORRT, n = 29). Despite a median MELD of 39, overall 30-day, 1-, 3- and 5-year survivals were 93%, 75%, 68% and 65%, respectively. Em-IORRT recipients had significantly more intraoperative complications (arrhythmias, postreperfusion syndrome, coagulopathy) compared with both No-IORRT and Pl-IORRT and greater 30-day graft loss (28% vs. 10%, p = 0.004) and need for retransplantation (24% vs. 10%, p = 0.099) compared with No-IORRT. A risk score based on multivariate predictors of IORRT accurately identified recipients with chronic (sensitivity 84%, specificity 72%, concordance-statistic [c-statistic] 0.829) and acute (sensitivity 93%, specificity 61%, c-statistic 0.776) liver failure requiring IORRT. In this largest experience of LT in recipients receiving RRT, we report excellent survival and propose a practical model that accurately identifies recipients who may benefit from IORRT. For this select group, timely initiation of IORRT reduces intraoperative complications and improves posttransplant outcomes.

Published
2014

8. Phase Ib dose-escalation study of the hypoxia-modifier myo-inositol trispyrophosphate in patients with hepatopancreatobiliary tumors

Author

Schneider, M, primary, Linecker, M, additional, Fritsch, R, additional, Mühlematter, U, additional, Stocker, D, additional, Pestalozzi, B, additional, Samaras, P, additional, Jetter, A, additional, Kron, P, additional, Petrowsky, H, additional, Nicolau, C, additional, Lehn, J-M, additional, Humar, B, additional, Graf, R, additional, Clavien, P-A, additional, and Limani, P, additional

Published
2022
Full Text
View/download PDF

9. Robotic distal pancreatectomy, a novel standard of care? First benchmark values for surgical outcomes from 14 international expert centers

Author

Müller, P, primary, Breuer, E, additional, Tschuor, C, additional, Saint-Marc, O, additional, Keck, T, additional, Coratti, A, additional, De Oliveira, M, additional, Allen, P, additional, Giulianotti, P, additional, Oberkofler, C, additional, Nickel, F, additional, Groot Koerkamp, B, additional, Martinie, J, additional, Yeo, C, additional, Hackert, T, additional, Petrowsky, H, additional, He, J, additional, Boggi, U, additional, Borel-Rinkes, I H, additional, and Clavien, P-A, additional

Published
2022
Full Text
View/download PDF

10. De Novo Malignancy After Liver Transplantation: Risk Assessment, Prevention, and Management-Guidelines From the ILTS-SETH Consensus Conference

Author

Colmenero J, Tabrizian P, Bhangui P, Pinato D, Rodriguez-Peralvarez M, Sapisochin G, Bhoori S, Pascual S, Senzolo M, Al-Adra D, Herrero J, Petrowsky H, Dawson L, Hosni A, Kutzke J, Gastaca M, and Watt K

Abstract

De novo malignancies (DNMs) following liver transplantation (LT) have been reported as 1 of the major causes of late mortality, being the most common cause of death in the second decade after LT. The overall incidence of DNMs is reported to be in the range of 3.1% to 14.4%, and the incidence is 2- to 3-fold higher in transplant recipients than in age- and sex-matched healthy controls. Long-term immunosuppressive therapy, which is the key in maintaining host tolerance and achieving good long-term outcomes, is known to contribute to a higher risk of DNMs. However, the incidence and type of DNM also depends on different risk factors, including patient demographics, cause of the underlying chronic liver disease, behavior (smoking and alcohol abuse), and pre-existing premalignant conditions. The estimated standardized incidence ratio for different DNMs is also variable. The International Liver Transplantation Society-Spanish Society of Liver Transplantation Consensus Conference working group on DNM has summarized and discussed the current available literature on epidemiology, risk factors, management, and survival after DNMs. Recommendations for screening and surveillance for specific tumors, as well as immunosuppression and cancer-specific management in patients with DNM, are summarized.

Published
2022

13. Building a Successful Hepatic Artery Infusion (HAI) Program: An International Survey of the HAI Consortium Research Network

Author

Cavnar, M., primary, Ghalambor, T., additional, Lidsky, M., additional, Dominguez, I., additional, Karanicolas, P., additional, Merkow, R., additional, Mayo, S., additional, Rocha, F., additional, Fields, R., additional, Koerkamp, B. Groot, additional, Yopp, A., additional, Petrowsky, H., additional, D’Angelica, M., additional, and Gholami, S., additional

Published
2022
Full Text
View/download PDF

26. Benchmarks in pancreatic surgery. A novel tool for unbiased outcome comparisons

Author

Sánchez-Velázquez, Patricia, primary, Muller, X., additional, Malleo, G., additional, Park, J.S., additional, Hwang, H.K., additional, Napoli, N., additional, Javed, A., additional, Inoue, Y., additional, Beghdadi, N., additional, Kalisvaart, M., additional, Vigia, E., additional, Walsh, C., additional, Lovasik, B., additional, Busquets, J., additional, Scandavini, C., additional, Robin, R., additional, Hideyuki, Y., additional, Mackay, T.M., additional, Busch, O., additional, Hartog, H., additional, Heinrich, S., additional, Gleisner, A., additional, Perinel, J., additional, Passeri, M., additional, Lluis, N., additional, Raptis, D.A., additional, Tschuor, C., additional, Oberkofler, C.E., additional, De Oliveira, M.L., additional, Petrowsky, H., additional, and Martinie, J., additional

Published
2020
Full Text
View/download PDF

27. Corrected age-adjusted Charlson Comorbidity Index (CaCCI) for patients undergoing ALPPS: A tool for preoperative patients selection.

Author

Capobianco, I., primary, Oldhafer, K., additional, Fard-Aghaie, M., additional, Campos, R Robles, additional, Brusadin, R., additional, Petrowsky, H., additional, Linecker, M., additional, Mehrabi, A., additional, Hoffmann, K., additional, Li, J., additional, Hernández-Alejandro, R., additional, Tun-Abraham, M.E., additional, Jovine, E., additional, Serenari, M., additional, Björnsson, B., additional, Alikhanov, R., additional, Efanov, M., additional, Muiesan, P., additional, Schlegel, A., additional, Van Gulik, T.M., additional, Olthof, P.B., additional, Stavrou, G., additional, Königsrainer, A., additional, and Nadalin, S., additional

Published
2020
Full Text
View/download PDF

30. β6‐integrin serves as a novel serum tumor marker for colorectal carcinoma

Author

Bengs, S. (Susan), Becker, E. (Eugenia), Busenhart, P. (Philipp), Spalinger, M. R. (Marianne R.), Raselli, T. (Tina), Kasper, S. (Stephanie), Lang, S. (Silvia), Atrott, K. (Kirstin), Mamie, C. (Celine), Vavricka, S. R. (Stephan R.), von Boehmer, L. (Lotta), Knuth, A. (Alexander), Tuomisto, A. (Anne), Mäkinen, M. J. (Markus J.), Hruz, P. (Petr), Turina, M. (Matthias), Rickenbacher, A. (Andreas), Petrowsky, H. (Henrik), Weber, A. (Achim), Frei, P. (Pascal), Halama, M. (Marcel), Jenkins, G. (Gisli), Sheppard, D. (Dean), Croner, R. S. (Roland S.), Christoph, J. (Jan), Britzen-Laurent, N. (Nathalie), Naschberger, E. (Elisabeth), Schellerer, V. (Vera), Stürzl, M. (Michael), Fried, M. (Michael), Rogler, G. (Gerhard), and Scharl, M. (Michael)

Subjects
therapy response, surveillance, metastasis, colorectal cancer, neoplasms, ITGB6, digestive system diseases, serum tumor marker
Abstract

Colorectal cancer (CRC) is one of the leading causes of cancer‐related deaths worldwide and the need for novel biomarkers and therapeutic strategies to improve diagnosis and surveillance is obvious. This study aims to identify β6‐integrin (ITGB6) as a novel serum tumor marker for diagnosis, prognosis, and surveillance of CRC. ITGB6 serum levels were validated in retro‐ and prospective CRC patient cohorts. ITGB6 serum levels were analyzed by ELISA. Using an initial cohort of 60 CRC patients, we found that ITGB6 is present in the serum of CRC, but not in non‐CRC control patients. A cut‐off of ≥2 ng/mL ITGB6 reveals 100% specificity for the presence of metastatic CRC. In an enlarged study cohort of 269 CRC patients, ITGB6 predicted the onset of metastatic disease and was associated with poor prognosis. Those data were confirmed in an independent, prospective cohort consisting of 40 CRC patients. To investigate whether ITGB6 can also be used for tumor surveillance, serum ITGB6‐levels were assessed in 26 CRC patients, pre‐ and post‐surgery, as well as during follow‐up visits. After complete tumor resection, ITGB6 serum levels declined completely. During follow‐up, a new rise in ITGB6 serum levels indicated tumor recurrence or the onset of new metastasis as confirmed by CT scan. ITGB6 was more accurate for prognosis of advanced CRC and for tumor surveillance as the established marker carcinoembryonic antigen (CEA). Our findings identify ITGB6 as a novel serum marker for diagnosis, prognosis, and surveillance of advanced CRC. This might essentially contribute to an optimized patient care.

Published
2019

36. Clearing the Future Liver Remnant by Intraoperative Surgical Thermal Ablation or Wedge Resection as an Extension for the ALPPS Procedure in Colorectal Liver Metastases

Author

Wahba, R., Stippel, D., Linecker, M., Petrowsky, H., Thomas, M.N., R.R. datta, Robles-Campos, R., Tomassine, F., Troisi, R., Vrochides, D., Vicente, E., Mehrabi, A., Fernandez-Placencia, R., Romic, I., Hernandez-Alejandro, R., Dede, K., Voskanyan, S., Rauchfuss, F., Balci, D., Li, J., Björnsson, B., Sparrelid, E., Hellmich, M., Clavien, P.-A., and Bruns, C.J.

Published
2022
Full Text
View/download PDF

39. Performance validation of the ALPPS risk model

Author

Linecker, M., primary, Kambakamba, P., additional, Schlegel, A., additional, Muiesan, P., additional, Capobianco, I., additional, Nadalin, S., additional, Torres, O., additional, Mehrabi, A., additional, Stavrou, G.A., additional, Oldhafer, K.J., additional, Lurje, G., additional, Neumann, U., additional, Robles-Campos, R., additional, Hernandez-Alejandro, R., additional, Malago, M., additional, De Santibanes, E., additional, Clavien, P.-A., additional, and Petrowsky, H., additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results